MUPIROCIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Mupirocin, and what generic alternatives are available?
Mupirocin is a drug marketed by Alembic, Amneal, Encube, Glenmark Pharms Inc, Padagis Israel, Taro, Fougera Pharms, Glenmark Pharms, and Teva. and is included in eleven NDAs.
The generic ingredient in MUPIROCIN is mupirocin. There are sixteen drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the mupirocin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Mupirocin
A generic version of MUPIROCIN was approved as mupirocin by PADAGIS ISRAEL on November 7th, 2003.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MUPIROCIN?
- What are the global sales for MUPIROCIN?
- What is Average Wholesale Price for MUPIROCIN?
Summary for MUPIROCIN
| US Patents: | 0 |
| Applicants: | 9 |
| NDAs: | 11 |
| Finished Product Suppliers / Packagers: | 25 |
| Raw Ingredient (Bulk) Api Vendors: | 87 |
| Clinical Trials: | 82 |
| Patent Applications: | 5,308 |
| Drug Prices: | Drug price information for MUPIROCIN |
| Drug Sales Revenues: | Drug sales revenues for MUPIROCIN |
| DailyMed Link: | MUPIROCIN at DailyMed |
Recent Clinical Trials for MUPIROCIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Victoriano Luna Medical Center | Early Phase 1 |
| Jiangxi Provincial Cancer Hospital | Phase 3 |
| Future University in Egypt | Phase 2/Phase 3 |
Pharmacology for MUPIROCIN
| Drug Class | RNA Synthetase Inhibitor Antibacterial |
| Mechanism of Action | RNA Synthetase Inhibitors |
Medical Subject Heading (MeSH) Categories for MUPIROCIN
Anatomical Therapeutic Chemical (ATC) Classes for MUPIROCIN
US Patents and Regulatory Information for MUPIROCIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alembic | MUPIROCIN | mupirocin calcium | CREAM;TOPICAL | 213053-001 | Nov 16, 2021 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Fougera Pharms | MUPIROCIN | mupirocin | OINTMENT;TOPICAL | 065192-001 | Nov 30, 2005 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Glenmark Pharms Inc | MUPIROCIN | mupirocin calcium | CREAM;TOPICAL | 201587-001 | Jan 24, 2013 | AB | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Glenmark Pharms | MUPIROCIN | mupirocin | OINTMENT;TOPICAL | 090480-001 | Jun 8, 2011 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Amneal | MUPIROCIN | mupirocin calcium | CREAM;TOPICAL | 214811-001 | Nov 15, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Encube | MUPIROCIN | mupirocin calcium | CREAM;TOPICAL | 213076-001 | Aug 31, 2021 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
